Literature DB >> 8718505

Hydrops fetalis and neonatal leukemia in Down syndrome.

A Zipursky1, T Rose, M Skidmore, P Thorner, J Doyle.   

Abstract

Four newborn infants with Down syndrome and manifestations of neonatal leukemia are described. One of the four was stillborn, two died shortly after birth, and a fourth survived and all evidence of leukemia disappeared in the first month of life. Three of the four cases had hydrops fetalis, and a fourth was a macerated stillborn. Nine other similar reported cases are reviewed. We conclude that neonatal leukemia in Down syndrome is a form of leukemia that is usually transient, with spontaneous recovery, but may be fatal at or around the time of birth with manifestations of hydrops fetalis, hepatosplenomegaly, and/or progressive liver disease.

Entities:  

Mesh:

Year:  1996        PMID: 8718505     DOI: 10.3109/08880019609033374

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis.

Authors:  Myoung Ja Park; Manabu Sotomatsu; Kentaro Ohki; Kokoro Arai; Kenichi Maruyama; Tomio Kobayashi; Akira Nishi; Kiyoko Sameshima; Takeshi Takagi; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

2.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

3.  Management of Duodenal Atresia in the setting of Congenital Leukemia with Massive Hepatomegaly.

Authors:  Sathyaprasad C Burjonrappa
Journal:  J Neonatal Surg       Date:  2013-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.